With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...
After high-profile moves by Eli Lilly and other Big Pharmas to pause their U.K. | The company is looking to work out an ...
Promotional materials for a handful of biologics have found their way into the FDA’s hot seat. | Promotional materials for a handful of biologics have found their way into the FDA’s hot seat.
Takeda has started a workforce reduction in the U.S. as the company aims to save more than 200 billion Japanese yen ($1.26 billion) in annual costs. | Takeda has started a workforce reduction in the U ...
After Spinraza's FDA approval nearly a decade ago, Biogen's spinal muscular atrophy (SMA) drug captured rapid momentum and delivered blockbuster-level sales in just its second year on the market. | ...
After notching a phase 2 trial win, Idorsia’s insomnia med Quviviq (daridorexant) is one step closer to potentially becoming a first-in-class treatment for children. | After notching a phase 2 trial ...
High-flying Samsung Biologics is facing a rare bit of public turbulence after the CDMO’s labor union secured the votes needed to strike, signaling a potential escalation in an impasse over what the | ...
Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's ...
With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit. | Rocket ...
There’s no need to dive fast and furious into every single wellness trend, according to a Ludacris-fronted campaign from ...
Addressing pressing questions about upcoming ATTR-CM competition and market opportunity, Alnylam management on Tuesday ...
Amid an outpouring of pharma investment dollars into China, Novartis is the latest multinational drugmaker lining up to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results